Beleave Inc, a Toronto-based cultivator and seller of medical cannabis and producer of cannabis oils and extracts, has secured an investment of up to $20 million from U.S. private equity firm Alumina Partners.
Under the deal’s terms, Beleave will be able to draw down capital as needed in a series of private placements of a minimum of $2 million.
The proceeds will be used by the company to take advantage of new opportunities in the regulated cannabis sector, increase operating flexibility, and strengthen its balance sheet.
Beleave is led by CEO Andrew Wnek.
Beleave Announces Investment Agreement for up to $20 Million with Alumina Partners
TORONTO, Sept. 14, 2018 /CNW/ – Beleave Inc. (CSE: BE) (OTCQX: BLEVF) (“Beleave” or the “Company”) is pleased to announce it has entered into a non-exclusive investment agreement with Alumina Partners, LLC, a New York-based private investment partnership, providing the availability of up to CAD $20 million over a 24-month period, to take advantage of new opportunities, increase operating flexibility, and strengthen the Company’s balance sheet. The terms of the agreement will allow Beleave to draw down capital at will, on an as-needed basis, in a series of equity private placements of a minimum of CAD $2 million in accordance with exchange policies. The objective is to provide Beleave with more flexible access to capital at the Company’s sole discretion.
“This agreement underpins Beleave’s ability to execute on growth initiatives in line with our strategic plan without any firm obligation to use this capital,” said Beleave Chief Financial Officer, Bojan Krasic. “We continue to grow as a company and are always looking for optionality when it comes to obtaining new sources of future capital.”
Pursuant to the terms of the agreement, Alumina Partners will commit to purchase up to CAD $20 million of units of the Company, consisting of one common share and one common share purchase warrant. Unit price will be determined within the regulatory issuance maximum discount of up to 25% of share price at the time of drawdown. Each offering occurring exclusively at the option of the Company, throughout the term of the agreement. The exercise price of the warrants will be at a 25% premium over the market price at time of issuance.
“We are delighted to support Beleave as they execute their plans and work to advance initiatives on several fronts of the regulated cannabis space,” added Adi Nahmani, Managing Member of Alumina Partners, LLC. “We were deeply impressed by the scale and scope of their planned diversified footprint, and look forward to seeing new shareholder value unlocked as the industry evolves and Beleave expands with it.”
ABOUT BELEAVE INC.
Beleave Inc. is a biotech company who’s wholly-owned subsidiary Beleave Kannabis Corp. is licensed to cultivate and sell medical cannabis and produce cannabis oils and extracts pursuant to Health Canada’s Access to Cannabis for Medical Purpose Relations. Beleave has developed a network of medical cannabis clinics under the Medi-Green banner and has applied for various patents to broaden its strong research focused foundation.
For further information: Investor Relations Contact: Richard Oyelowo, Phone : 1 (833) 375-9995, Email : firstname.lastname@example.org; Media Relations Contact : Grant McLeod, SVP, Regulatory Affairs and General Counsel, Phone : (416) 910-3401, Email : email@example.com